Liver grafts with major extended donor criteria may expand the organ pool for patients with hepatocellular carcinoma

Journal of Clinical Medicine

Volumn 8, Issue 10, 2019, Pages

  Lozanovski, Vladimir J ^a,b   Kerr, Larissa T B ^a   Khajeh, Elias ^a   Ghamarnejad, Omid ^a   Pfeiffenberger, Jan ^a,b   Hoffmann, Katrin ^a,b   Chang, De Hua ^a,b   Mieth, Markus ^a   Longerich, Thomas ^a,b   Strobel, Oliver ^a,b   Weiss, Karl Heinz ^a,b   Büchler, Markus W ^a   Mehrabi, Arianeb ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

HCC; Liver transplantation; Major extended donor criteria

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN;

ADULT; ALCOHOLISM; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT ATRESIA; BODY MASS; CANCER GRADING; CHILD PUGH SCORE; CHRONIC HEPATITIS; CLINICAL OUTCOME; DISEASE MODEL; END STAGE LIVER DISEASE; EXPANDED CRITERIA DONOR; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT SURVIVAL; HEMOCHROMATOSIS; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC STEATOHEPATITIS; PRIMARY BILIARY CIRRHOSIS; RECURRENCE FREE SURVIVAL; RETRANSPLANTATION; RISK FACTOR; STEATOSIS; TREATMENT OUTCOME;

EID: 85085351000     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm8101692     Document Type: Article

References (48)

1. Lafaro, K.J.; Demirjian, A.N.; Pawlik, T.M. Epidemiology of Hepatocellular Carcinoma. Surg. Oncol. Clin. North Am. 2015, 24, 1–17. [CrossRef] [PubMed]
2. Pinna, A.D.; Yang, T.; Mazzaferro, V.; De Carlis, L.; Zhou, J.; Roayaie, S.; Shen, F.; Sposito, C.; Cescon, M.; Di Sandro, S.; et al. Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma. Ann. Surg. 2018, 268, 868–875. [CrossRef] [PubMed]
3. Lozanovski, V.J.; Khajeh, E.; Fonouni, H.; Pfeiffenberger, J.; Von Haken, R.; Brenner, T.; Mieth, M.; Schirmacher, P.; Michalski, C.W.; Weiss, K.H.; et al. The impact of major extended donor criteria on graft failure and patient mortality after liver transplantation. Langenbeck’s Arch. Surg. 2018, 403, 719–731. [CrossRef] [PubMed]
4. Sotiropoulos, G.C.; Paul, A.; Molmenti, E.; Lang, H.; Frilling, A.; Napieralski, B.P.; Nadalin, S.; Treckmann, J.; Brokalaki, E.I.; Gerling, T.; et al. Liver Transplantation for Hepatocellular Carcinoma in Cirrhosis within the Eurotransplant Area: An Additional Option with “Livers that Nobody Wants”. Transplant 2005, 80, 897–902. [CrossRef]
5. Jochmans, I.; Pirenne, J.; Samuel, U.; Van Rosmalen, M. Adult Liver Allocation in Eurotransplant. Transplantation 2017, 101, 1542–1550. [CrossRef]
6. Mehrabi, A.; Mood, Z.A.; Fonouni, H.; Kashfi, A.; Hillebrand, N.; Müller, S.A.; Encke, J.; Büchler, M.W.; Schmidt, J. A single-center experience of 500 liver transplants using the modified piggyback technique by Belghiti. Liver Transplant. 2009, 15, 466–474. [CrossRef]
7. Braat, A.E.; Blok, J.J.; Putter, H.; Adam, R.; Burroughs, A.K.; Rahmel, A.O.; Porte, R.J.; Rogiers, X.; Ringers, J.; European Liver and Intestine Transplant Association (ELITA); et al. The Eurotransplant Donor Risk Index in Liver Transplantation: ET-DRI. Arab. Archaeol. Epigr. 2012, 12, 2789–2796.
8. Der Bundesärztekammer, B. Richtlinien zur Organtransplantation gem. § 16 TPG. Dtsch Arztebl 2008, 105, 1461–1464. Available online: https://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-Ordner/RL/RiliOrgaWlOvLeberTx20190924.pdf (accessed on 21 January 2019).
9. Schemmer, P.; Nickkholgh, A.; Hinz, U.; Gerling, T.; Mehrabi, A.; Sauer, P.; Encke, J.; Friess, H.; Weitz, J.; Büchler, M. Extended donor criteria have no negative impact on early outcome after liver transplantation: A single-center multivariate analysis. Transpl. Proc. 2007, 39, 529–534. [CrossRef]
10. Klempnauer, J.; Schrem, H.; Reichert, B.; Frühauf, N.; Becker, T.; Lehner, F.; Kleine, M.; Bektas, H.; Zachau, L. The Donor-Risk-Index, ECD-Score and D-MELD-Score all fail to predict short-term outcome after liver transplantation with acceptable sensitivity and specificity. Ann. Transplant. 2012, 17, 5–13. [CrossRef]
11. Bruns, H.; Lozanovski, V.J.; Schultze, D.; Hillebrand, N.; Hinz, U.; Büchler, M.W.; Schemmer, P. Prediction of Postoperative Mortality in Liver Transplantation in the Era of MELD-Based Liver Allocation: A Multivariate Analysis. PLoS ONE 2014, 9, e98782. [CrossRef] [PubMed]
12. Lee, D.D.; Croome, K.P.; Shalev, J.A.; Musto, K.R.; Sharma, M.; Keaveny, A.P.; Taner, C.B. Early allograft dysfunction after liver transplantation: An intermediate outcome measure for targeted improvements. Ann. Hepatol. 2016, 15, 53–60. [CrossRef] [PubMed]
13. Goldberg, D.; French, B.; Newcomb, C.; Liu, Q.; Sahota, G.; Wallace, A.E.; Forde, K.A.; Lewis, J.D.; Halpern, S.D. Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease. Clin. Gastroenterol. Hepatol. 2016, 14, 1638–1646.e2. [CrossRef] [PubMed]
14. Rahbari, N.N.; Mehrabi, A.; Mollberg, N.M.; Müller, S.A.; Koch, M.; Büchler, M.W.; Weitz, J. Hepatocellular carcinoma: Current management and perspectives for the future. Ann. Surg. 2011, 253, 453–469. [CrossRef]
15. Yao, F.; Bass, N.M.; Nikolai, B.; Merriman, R.; Davern, T.J.; Kerlan, R.; Ascher, N.L.; Roberts, J.P. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy. Liver Transplant. 2003, 9, 684–692. [CrossRef]
16. Adam, R.; Karam, V.; Cailliez, V.; O Grady, J.G.; Mirza, D.; Cherqui, D.; Klempnauer, J.; Salizzoni, M.; Pratschke, J.; Jamieson, N.; et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR)—50-year evolution of liver transplantation. Transpl. Int. 2018, 31, 1293–1317. [CrossRef]
17. Kim, W.; Lake, J.; Smith, J.; Schladt, D.; Skeans, M.; Noreen, S.; Robinson, A.; Miller, E.; Snyder, J.; Israni, A. OPTN/SRTR 2017 Annual Data Report: Liver. Am. J. Transplant. 2019, 19, 184–283. [CrossRef]
18. Mittal, S.; El-Serag, H.B. Epidemiology of HCC: Consider the population. J. Clin. Gastroenterol. 2013, 47, S2–S6. [CrossRef]
19. Statistics Report Library. Available online: http://statistics.eurotransplant.org/index.php?search_type= &search_organ=liver&search_region=by+country&search_period=2018&search_characteristic=&search_ text (accessed on 15 January 2019).
20. Adler, M.; De Pauw, F.; Vereerstraeten, P.; Fancello, A.; Lerut, J.; Starkel, P.; Van Vlierberghe, H.; Troisi, R.; Donckier, V.; Detry, O.; et al. Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transpl. 2008, 14, 526–533. [CrossRef]
21. De Boer, J.D.; Blok, J.J.; Putter, H.; Koopman, J.J.; van Hoek, B.; Samuel, U.; van Rosmalen, M.; Metselaar, H.J.; Alwayn, I.P.; Guba, M.; et al. Optimizing the use of geriatric livers for transplantation in the Eurotransplant region. Liver Transpl. 2019, 25, 260–274. [CrossRef]
22. Goldaracena, N.; Gorgen, A.; Doyle, A.; Hansen, B.E.; Tomiyama, K.; Zhang, W.; Ghanekar, A.; Lilly, L.; Cattral, M.; Galvin, Z.; et al. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. J. Hepatol. 2019, 70, 666–673. [CrossRef] [PubMed]
23. Shan, Y.; Huang, L.; Xia, Q. Salvage Liver Transplantation Leads to Poorer Outcome in Hepatocellular Carcinoma Compared with Primary Liver Transplantation. Sci. Rep. 2017, 7, 44652. [CrossRef] [PubMed]
24. Merion, R.; Wolfe, R.A.; Dykstra, D.M.; Leichtman, A.B.; Gillespie, B.; Held, P.J. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl. 2003, 9, 12–18. [CrossRef] [PubMed]
25. Nocito, A.; El-Badry, A.M.; Clavien, P.-A. When is steatosis too much for transplantation? J. Hepatol. 2006, 45, 494–499. [CrossRef]
26. Linares, I.; Hamar, M.; Selzner, N.; Selzner, M. Steatosis in Liver Transplantation: Current Limitations and Future Strategies. Transplantation 2019, 103, 78–90. [CrossRef]
27. Dutkowski, P.; Schlegel, A.; Slankamenac, K.; Oberkofler, C.E.; Adam, R.; Burroughs, A.K.; Schadde, E.; Müllhaupt, B.; Clavien, P.-A. The use of fatty liver grafts in modern allocation systems: Risk assessment by the balance of risk (BAR) score. Ann. Surg. 2012, 256, 861–868. [CrossRef]
28. Pratschke, S.; Bender, A.; Boesch, F.; Andrassy, J.; Van Rosmalen, M.; Samuel, U.; Rogiers, X.; Meiser, B.; Küchenhoff, H.; Driesslein, D.; et al. Association between donor age and risk of graft failure after liver transplantation: An analysis of the Eurotransplant database. Transpl. Int. 2018, 32, 270–279. [CrossRef]
29. Durand, F.; Levitsky, J.; Cauchy, F.; Gilgenkrantz, H.; Soubrane, O.; Francoz, C. Age and liver transplantation. J. Hepatol. 2019, 70, 745–758. [CrossRef]
30. Feng, S.; Lai, J.C. Expanded criteria donors. Clin. Liver Dis. 2014, 18, 633–649. [CrossRef]
31. Haugen, C.E.; Bowring, M.G.; Holscher, C.M.; Jackson, K.R.; Garonzik-Wang, J.; Cameron, A.M.; Philosophe, B.; McAdams-DeMarco, M.; Segev, D.L. Survival Benefit of Accepting Livers from Deceased Donors over 70 Years Old. Am. J. Transpl. 2019, 19, 2020–2028. [CrossRef]
32. Halazun, K.; Rana, A.; Fortune, B.; Quillin III, R.; Verna, E.; Samstein, B.; Guarrera, J.; Kato, T.; Griesemer, A.; Fox, A. No country for old livers? Examining and optimizing the utilization of elderly liver grafts. Am. J. Transpl. 2018, 18, 669–678. [CrossRef] [PubMed]
33. Paterno, F.; Wima, K.; Hoehn, R.S.; Cuffy, M.C.; Diwan, T.S.; Woodle, S.E.; Abbott, D.E.; Shah, S.A. Use of Elderly Allografts in Liver Transplantation. Transplantation 2016, 100, 153–158. [CrossRef] [PubMed]
34. Lake, J.R.; Shorr, J.S.; Steffen, B.J.; Chu, A.H.; Gordon, R.D.; Wiesner, R.H. Differential Effects of Donor Age in Liver Transplant Recipients Infected With Hepatitis B, Hepatitis C and Without Viral Hepatitis. Arab. Archaeol. Epigr. 2005, 5, 549–557. [CrossRef] [PubMed]
35. Rupp, C.; Hippchen, T.; Neuberger, M.; Sauer, P.; Pfeiffenberger, J.; Stremmel, W.; Gotthardt, D.N.; Mehrabi, A.; Weiss, K.-H. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. World J. Gastroenterol. 2018, 24, 1353–1360. [CrossRef] [PubMed]
36. Gao, Q.; Mulvihill, M.S.; Scheuermann, U.; Davis, R.P.; Yerxa, J.; Yerokun, B.A.; Hartwig, M.G.; Sudan, D.L.; Knechtle, S.J.; Barbas, A.S. Improvement in Liver Transplant Outcomes From Older Donors: A US National Analysis. Ann. Surg. 2019, 270, 333–339. [CrossRef] [PubMed]
37. Nagai, S.; Yoshida, A.; Facciuto, M.; Moonka, D.; Abouljoud, M.S.; Schwartz, M.E.; Florman, S.S. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology 2015, 61, 895–904. [CrossRef] [PubMed]
38. Oweira, H.; Lahdou, I.; Daniel, V.; Opelz, G.; Schmidt, J.; Zidan, A.; Mehrabi, A.; Sadeghi, M. Early post-operative acute phase response in patients with early graft dysfunction is predictive of 6-month and 12-month mortality in liver transplant recipients. Hum. Immunol. 2016, 77, 952–960. [CrossRef]
39. Kern, B.; Feurstein, B.; Fritz, J.; Fabritius, C.; Sucher, R.; Graziadei, I.; Bale, R.; Tilg, H.; Zoller, H.; Newsome, P.; et al. High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation. Eur. J. Gastroenterol. Hepatol. 2019, 31, 205–210. [CrossRef]
40. Selck, F.W.; Grossman, E.B.; Ratner, L.E.; Renz, J.F. Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: Implications for further expansion of the deceased-donor pool. Ann. Surg. 2008, 248, 599–607. [CrossRef]
41. Moosburner, S.; Ritschl, P.; Wiering, L.; Gassner, J.; Öllinger, R.; Pratschke, J.; Sauer, I.; Raschzok, N. High donor age for liver transplantation: Tackling organ scarcity in Germany. Chirurg 2019, 90, 744–751. [CrossRef]
42. Mehta, N.; Heimbach, J.; Lee, D.; Dodge, J.L.; Harnois, D.; Burns, J.; Sanchez, W.; Roberts, J.P.; Yao, F.Y. Wait time of less than 6 and greater than 18 months predicts hepatocellular carcinoma recurrence after liver transplantation: Proposing a wait time “Sweet Spot”. Transplantation 2017, 101, 2071–2078. [CrossRef] [PubMed]
43. De Carlis, L.; Di Sandro, S.; Centonze, L.; Lauterio, A.; Buscemi, V.; De Carlis, R.; Ferla, F.; Sguinzi, R.; Okolicsanyi, S.; Belli, L.; et al. Liver-allocation policies for patients affected by HCC in Europe. Curr. Transplant. Rep. 2016, 3, 313–318. [CrossRef] [PubMed]
44. Regalia, E.; Doci, R.; Andreola, S.; Montalto, F.; Ammatuna, M.; Mazzaferro, V.M.; Pulvirenti, A.; Bozzetti, F.; Morabito, A.; Gennari, L. Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. New Engl. J. Med. 1996, 334, 693–700.
45. Mazzaferro, V.M.; Llovet, J.M.; Miceli, R.; Bhoori, S.; Schiavo, M.; Mariani, L.; Camerini, T.; Roayaie, S.; Schwartz, M.E.; Grazi, G.L.; et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol. 2009, 10, 35–43. [CrossRef]
46. Jin, B.; Liu, C.Z.; Hu, S.Y.; Wang, T.T.; Wang, L.; Jiang, X.S.; Frezza, E.E. Influence of estrogen and androgen on the outcome of liver transplantation. Hepatogastroenterology 2008, 55, 207–211.
47. Brooks, B.K.; Levy, M.F.; Jennings, L.W.; Abbasoglu, O.; Vodapally, M.; Goldstein, R.M.; Husberg, B.S.; Gonwa, T.A.; Klintmalm, G.B. Influence of Donor and Recipient Gender on the Outcome of Liver Transplantation12. Transplantation 1996, 62, 1784–1787. [CrossRef]
48. Reese, P.P.; Sonawane, S.B.; Thomasson, A.; Yeh, H.; Markmann, J.F. Donor Age and Cold Ischemia Interact to Produce Inferior 90-Day Liver Allograft Survival. Transplantation 2008, 85, 1737–1744. [CrossRef]